Weekly company factor report
M3V
MeVis Medical Solutions AG
Current comparison
Latest company comparison
The scores rank this company against other measured companies in the selected market. Open each section to check the figures behind them.
Current factor profile
Valuation and financial-strength measures both rank above most companies in the selected market. The completed price record is weak and does not support the other measures yet.
Capital returned is supported by cash flow
Shareholder yield is 4.0% and free-cash-flow yield is 9.5%. The cash-flow figure supports the reported distribution.
Four main ranks
Company profile
Completed weekly snapshots
How the ranks have changed
Ready-made approaches
Which screens include this company
Passing a screen means the latest completed snapshot meets that screen’s published rules. It is not a recommendation.
Continue the research
Check the supporting evidence
Open the price record, technical position, market group or other company research that is available for M3V.
Price against company results
Value
A higher value rank means the shares are cheaper on the combined definitions relative to this market. Negative earnings or cash flow need separate attention.
Current reading
Free-cash-flow yield is 9.5%, providing cash support for the valuation.
Value measures compared
Raw multiples and yields
P/E history
P/E is shown only when trailing earnings are positive.
Research path
How to test this valuation
A low valuation is a starting point. These checks show whether the earnings base, cash flow and completed price record support it.
Profitability, cash and balance sheet
Financial strength
The rank combines several company measures. The chart and figures below keep profitability, leverage and cash conversion visible separately.
Financial measures compared
Profitability and leverage
Completed returns and variability
Price performance and risk
Returns show direction; volatility and drawdown show how uneven the path has been. Both are based on completed prices.
Current reading
Near-term vol (45%) is expanding vs long-term (19%) — risk is increasing.
Returns over several periods
Recent and one-year volatility
How long the current readings have persisted
| Measure | Current | Current run | Direction |
|---|---|---|---|
| OS Composite | 0.760 | Unchanged for 2 snapshots | improving |
| Value %ile | 0.590 | Unchanged for 0 snapshots | improving |
| Quality %ile | 0.890 | Unchanged for 10 snapshots | deteriorating |
| Momentum %ile | 0.340 | Unchanged for 0 snapshots | stable |
| F-Score | 6.000 | Unchanged for 0 snapshots | stable |
| Confidence | 0.823 | Unchanged for 10 snapshots | deteriorating |
| Volatility | 0.191 | Unchanged for 10 snapshots | improving |
Like-for-like context
Sector comparison
The company is compared with measured companies in Healthcare for the same completed factor week.
Company against sector
Valuation distance from sector
| Company | Combined | Value | Financial strength | Price performance |
|---|---|---|---|---|
| MED MEDICLIN Aktiengesellschaft | 99.0 | 97.0 | 84.0 | 80.0 |
| NOV Novo Nordisk A/S | 98.0 | 98.0 | 83.0 | 79.0 |
| DRW8 Drägerwerk AG & Co. KGaA | 97.0 | 93.0 | 57.0 | 82.0 |
| CBHD Coloplast A/S | 96.0 | 97.0 | 92.0 | 35.0 |
| DMP Dermapharm Holding SE | 95.0 | 71.0 | 93.0 | 74.0 |
| M12 M1 Kliniken AG | 95.0 | 72.0 | 92.0 | 77.0 |
| BRM Bristol-Myers Squibb Company | 93.0 | 61.0 | 98.0 | 81.0 |
| AJ91 DocCheck AG | 92.0 | 88.0 | 82.0 | 40.0 |
Reported company accounts
Company figures
Quarterly and annual figures are kept separate. The dates below show the latest accepted reporting periods.
Annual figures
Revenue
Net income
Free cash flow
Net margin
Operating income
Operating cash flow
Capital expenditure
Equity and liabilities
Definitions and source checks
Measures and data
Each figure is shown with its plain definition. Percentile ranks compare the company with the selected market for the same completed week.
Value measures · Price compared with earnings, sales, assets and cash flow
Financial strength · Profitability, cash conversion and balance-sheet measures
Price performance · Completed price returns over several periods
Growth and stability · Revenue, earnings history and capital returned to shareholders
Combined value measures · Several valuation measures ranked together; 1 is cheapest
Capital use and company classification · Funding, distributions and company-size classifications
Company research path · week ending 9 Aug 2026
Company and valuation evidence are ahead of the price record
The company and valuation checks pass; completed price support is still building.
The path reads company results, valuation, completed price evidence and risk in that order. A later strength does not cancel an earlier weakness.
- ✓ Data readyPassed · 100/100 Published factors, company figures and completed prices are available.
- ✓ Company recordPassed · 71/100 Checks profitability, cash support, balance-sheet measures and their direction.
- ✓ Relative valuePassed · 59/100 Checks whether the current valuation compares well with the selected market.
- 4 Market supportNeeds more evidence · 42/100 Checks completed price performance, relative strength, trend and buying pressure.
- 5 Setup and riskNot reached · 38/100 Checks whether the price structure is usable without ignoring volatility or drawdown.
- 6 Full reviewNot reached Open the supporting company, market and risk research before making a decision.
Evidence used now
What moves the research path
Each block opens the report section containing the figures behind the score.
- Financial-strength rank 89/100
- F-Score 6/9
- 4 usable annual periods
- Value rank 59/100
- P/E 13.6×
- Free-cash-flow yield +9.5%
- Price-performance rank 34/100
- Six-month return +0.4%
- Relative strength -0.1
- Stage 1 · Basing
- Stage 1 · Basing
- Price at -7.2% of its 52-week high
- Completed price structure and risk combined
- One-year volatility 19.1%
- Recent volatility 44.8%
- 12-month drawdown -12.7%
Completed factor weeks
How the evidence has moved
All four lines are higher-is-better market ranks on the same 0–100 scale.
What the current evidence supports
- Company record scores 71/100.
- Risk check scores 85/100.
What still needs attention
- Relative value scores 59/100.
- Market support scores 42/100.
- Setup scores 38/100.
Next check
Wait for broader completed price, trend and relative-strength confirmation.
This path uses completed records and is recalculated with each published factor week. It is a research sequence, not a trade instruction.
Supporting Sharemaestro research
Continue with the available evidence
Only research pages with data for M3V are shown.